NCT06255782 - An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseOrnithine Carbamoyltransferase Deficiency (Disorder)Urea Cycle Disorders, Inborn

Interventions

GENETIC

ECUR-506

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Trial Locations (9)

3052

RECRUITING

The Royal Children's Hospital, Melbourne

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

80045

RECRUITING

Children's Hospital of Colorado, Anshutz Medical Campus, Aurora

90095

RECRUITING

UCLA Mattel Children's Hospital, Los Angeles

Unknown

RECRUITING

The Children's Hospital at Westmead, Sydney

RECRUITING

Great Ormond Street Hospital, London

RECRUITING

The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital, Newcastle upon Tyne

08950

RECRUITING

Hopsital Sant Joan de Deu, Barcelona

All Listed Sponsors

lead

iECURE, Inc.

INDUSTRY